Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977959 | 0.89 | SSTR4 (0.60) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4981608 | 0.85 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2POLBEPHX2 | |
| SCHEMBL4980231 | 0.82 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2EPHX2MCHR1 | |
| SCHEMBL10223935 | 0.78 | EPHX2 (0.72) | RAB9ANPC1SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL5466257 | 0.77 | MTNR1A (0.58) | MTNR1AMTNR1BNPC1MAPTSMN1; SMN2 | |
| SCHEMBL4981108 | 0.75 | KMT2A (0.58) | RAB9ANPC1MAPTSMN1; SMN2POLB | |
| SCHEMBL4982014 | 0.75 | SIGMAR1 (0.56) | RAB9ANPC1MAPTSMN1; SMN2POLB | |
| SCHEMBL4983996 | 0.75 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL4977767 | 0.74 | MCHR1 (0.65) | RAB9ANPC1SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL14263098 | 0.73 | MEN1 (0.77) | MAPTSMN1; SMN2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | MTNR1A 96/4885MTNR1B 97/4885RAB9A 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.